Ovarian Cancer
Feb 1, 2025, 16:18
Randomized phase III trial of adjuvant carboplatin and paclitaxel in epithelial ovarian cancer
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared an article by Jeffrey Bell, et al. on X:
“Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian cancer:
GOG 157: 3 cycles of chemo may be sufficient for high risk early stage EOC.”
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Authors: Jeffrey Bell, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 1, 2025, 16:11
Feb 1, 2025, 15:55
Feb 1, 2025, 14:47